imgn151
Generic: Opugotamig Olatansine·Code: IMGN151
imgn151: 2 clinical trials tracked.
imgn151 evidence translation
What we can confirm
2 tracked trials
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about imgn151, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (2)
A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers
Primary endpoint: Number of Participants With Dose-limiting Toxicities (DLTs)
InterventionalRandomizedopen377 targetStarted 2025-07Completion 2028-0221 sites · Israel, Japan, United StatesAbbVie
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers
Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Interventionalopen256 targetStarted 2023-01Completion 2027-0250 sites · Australia, Belgium, Canada, France…AbbVie